L-ASPARAGINASA EFECTOS ADVERSOS PDF
Efectos secundarios del tratamiento para la leucemia linfoblástica aguda .. ( PEG-L asparaginasa; Oncaspar®) administrada por inyección. O Vincristina. L-asparaginase, definition: alkylating anticancer drug used in the treatment of L -asparaginasa, definition: fármaco alquilante antineoplásico, utilizado para el Los efectos secundarios más comunes son nauseas, vómitos. y otros efectos adversos de este grupo de fármacos, ya que estos pacientes los efectos citotóxicos de la quimioterapia son mediados por diversos . Actinomicina D, metotrexato, andrógenos, L-asparaginasa, procarbazina, vincristina.
|Published (Last):||19 November 2010|
|PDF File Size:||17.43 Mb|
|ePub File Size:||7.13 Mb|
|Price:||Free* [*Free Regsitration Required]|
Date on which this record was first entered in the EudraCT database:. Trials with results Trials without results. Positive culture for bacteria or fungus within 14 days of the initiation of therapy 7. Pneumonia AND sponsor name. How to search [pdf].
For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.
Son aptos los sujetos que hayan sufrido una alergia previa a la asparaginasa PEG pero que puedan recibir Erwinia. Los sujetos deben haber finalizado todo tipo l-asparaginass inmunoterapia activa p.
The IMP has been designated in this indication as an orphan drug in the Community. Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Phase 1b – To assess the safety and tolerability of carfilzomib, alone and in combination with induction chemotherapy, for the treatment of children with relapsed or refractory acute lymphoblastic leukemia ALL -To determine the maximum tolerated dose MTD of carfilzomib in combination with l-asparabinasa chemotherapy.
The trial involves single efectis in the Member State concerned. Combination product that includes a device, but does not involve an Advanced Therapy.
l-asparaginasa efectos adversos pdf
Plans for treatment or care after the subject has ended the participation in the trial if it is different from the expected normal treatment of that condition. Subjects who have had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible.
Subjects are under 18 years old.
The duration of this interval must be approved by the Onyx study medical monitor. Subjects must have a efextos creatinine level that is?
EU Clinical Trials Register.
Time to toxicity will be evaluated to differentiate single-agent l-asapraginasa from carfilzomib in combination with induction chemotherapy? Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the l-asparainasa.
Trials with results Trials without results Clear advanced search filters. Age 18 years or younger at the time of study treatment initiation. Committee on Advanced therapies CAT has issued a classification for this product. Clear advanced search filters.
Known allergy to Captisol a cyclodextrin derivative used to solubilize carfilzomib; for a complete listing of Captisol-enabled drugs, see the Ligand Pharmaceuticals, Inc. Active treatment for graft-versus-host disease 6. Cancer AND drug name. Restricciones de tratamientos previos: Karnofsky or Lansky scores?
Known allergy to any of the drugs used in the study. Adequate liver function, defined as both of the following: Title of the trial for lay people, in easily understood, i.
Medicinas para Quimioterapia – Nombres de Medicina
Relapsed or Refractory Acute Lymphoblastic Leukemia. Review by the Competent Authority or Ethics Committee in the country concerned. IMP with orphan designation in the indication. A group of cancers that usually begins in the bone marrow and results in high numbers of abnormal white blood cells. For these items you should use the filters and not add them to your search l-awparaginasa in the text field.